These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21292688)

  • 1. Chromosome 17 alterations identify good-risk and poor-risk tumors independently of clinical factors in medulloblastoma.
    McCabe MG; Bäcklund LM; Leong HS; Ichimura K; Collins VP
    Neuro Oncol; 2011 Apr; 13(4):376-83. PubMed ID: 21292688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci.
    Pfister S; Remke M; Benner A; Mendrzyk F; Toedt G; Felsberg J; Wittmann A; Devens F; Gerber NU; Joos S; Kulozik A; Reifenberger G; Rutkowski S; Wiestler OD; Radlwimmer B; Scheurlen W; Lichter P; Korshunov A
    J Clin Oncol; 2009 Apr; 27(10):1627-36. PubMed ID: 19255330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early recurrence in standard-risk medulloblastoma patients with the common idic(17)(p11.2) rearrangement.
    Bien-Willner GA; López-Terrada D; Bhattacharjee MB; Patel KU; Stankiewicz P; Lupski JR; Pfeifer JD; Perry A
    Neuro Oncol; 2012 Jul; 14(7):831-40. PubMed ID: 22573308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic effect of whole chromosomal aberration signatures in standard-risk, non-WNT/non-SHH medulloblastoma: a retrospective, molecular analysis of the HIT-SIOP PNET 4 trial.
    Goschzik T; Schwalbe EC; Hicks D; Smith A; Zur Muehlen A; Figarella-Branger D; Doz F; Rutkowski S; Lannering B; Pietsch T; Clifford SC
    Lancet Oncol; 2018 Dec; 19(12):1602-1616. PubMed ID: 30392813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytogenetic evaluation of isochromosome 17q in posterior fossa tumors of children and correlation with clinical outcome in medulloblastoma. Detection of a novel chromosomal abnormality.
    DeChiara C; Borghese A; Fiorillo A; Genesio R; Conti A; D'Amore R; Pettinato G; Varone A; Maggi G
    Childs Nerv Syst; 2002 Aug; 18(8):380-4. PubMed ID: 12192498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients.
    Pan E; Pellarin M; Holmes E; Smirnov I; Misra A; Eberhart CG; Burger PC; Biegel JA; Feuerstein BG
    Clin Cancer Res; 2005 Jul; 11(13):4733-40. PubMed ID: 16000568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic classification of pediatric medulloblastoma based on chromosome 17p loss, expression of MYCC and MYCN, and Wnt pathway activation.
    Park AK; Lee SJ; Phi JH; Wang KC; Kim DG; Cho BK; Haberler C; Fattet S; Dufour C; Puget S; Sainte-Rose C; Bourdeaut F; Grill J; Delattre O; Kim SK; Park WY
    Neuro Oncol; 2012 Feb; 14(2):203-14. PubMed ID: 22090452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and molecular stratification of disease risk in medulloblastoma.
    Gilbertson R; Wickramasinghe C; Hernan R; Balaji V; Hunt D; Jones-Wallace D; Crolla J; Perry R; Lunec J; Pearson A; Ellison D
    Br J Cancer; 2001 Sep; 85(5):705-12. PubMed ID: 11531256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.
    Korshunov A; Remke M; Werft W; Benner A; Ryzhova M; Witt H; Sturm D; Wittmann A; Schöttler A; Felsberg J; Reifenberger G; Rutkowski S; Scheurlen W; Kulozik AE; von Deimling A; Lichter P; Pfister SM
    J Clin Oncol; 2010 Jun; 28(18):3054-60. PubMed ID: 20479417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial.
    Clifford SC; Lannering B; Schwalbe EC; Hicks D; O'Toole K; Nicholson SL; Goschzik T; Zur Mühlen A; Figarella-Branger D; Doz F; Rutkowski S; Gustafsson G; Pietsch T;
    Oncotarget; 2015 Nov; 6(36):38827-39. PubMed ID: 26420814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromosome 1q gain is not associated with a poor outcome in childhood medulloblastoma: requirements for the validation of potential prognostic biomarkers.
    Clifford SC; O'Toole K; Ellison DW
    Cell Cycle; 2009 Mar; 8(5):787. PubMed ID: 19221477
    [No Abstract]   [Full Text] [Related]  

  • 12. Accumulation of genomic aberrations during clinical progression of medulloblastoma.
    Korshunov A; Benner A; Remke M; Lichter P; von Deimling A; Pfister S
    Acta Neuropathol; 2008 Oct; 116(4):383-90. PubMed ID: 18704466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic alterations in childhood medulloblastoma analyzed by comparative genomic hybridization.
    Michiels EM; Weiss MM; Hoovers JM; Baak JP; Voûte PA; Baas F; Hermsen MA
    J Pediatr Hematol Oncol; 2002; 24(3):205-10. PubMed ID: 11990307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gain of 1q is a potential univariate negative prognostic marker for survival in medulloblastoma.
    Lo KC; Ma C; Bundy BN; Pomeroy SL; Eberhart CG; Cowell JK
    Clin Cancer Res; 2007 Dec; 13(23):7022-8. PubMed ID: 18056178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of chromosome 17 abnormalities in medulloblastomas.
    Aldosari N; Rasheed BK; McLendon RE; Friedman HS; Bigner DD; Bigner SH
    Acta Neuropathol; 2000 Apr; 99(4):345-51. PubMed ID: 10787031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chromosome 17 abnormalities in medulloblastomas and their prognostic value].
    Korshunov AG; Sycheva RV; Gorelyshev SK; Ozerov SS; Golanov AV
    Zh Vopr Neirokhir Im N N Burdenko; 2008; (2):3-5; discussion 5. PubMed ID: 18724421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables.
    Ellison DW; Kocak M; Dalton J; Megahed H; Lusher ME; Ryan SL; Zhao W; Nicholson SL; Taylor RE; Bailey S; Clifford SC
    J Clin Oncol; 2011 Apr; 29(11):1400-7. PubMed ID: 20921458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of chromosome 17p loss with clinical outcome in medulloblastoma.
    Emadian SM; McDonald JD; Gerken SC; Fults D
    Clin Cancer Res; 1996 Sep; 2(9):1559-64. PubMed ID: 9816333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biological and clinical heterogeneity of MYCN-amplified medulloblastoma.
    Korshunov A; Remke M; Kool M; Hielscher T; Northcott PA; Williamson D; Pfaff E; Witt H; Jones DT; Ryzhova M; Cho YJ; Wittmann A; Benner A; Weiss WA; von Deimling A; Scheurlen W; Kulozik AE; Clifford SC; Peter Collins V; Westermann F; Taylor MD; Lichter P; Pfister SM
    Acta Neuropathol; 2012 Apr; 123(4):515-27. PubMed ID: 22160402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system.
    Biegel JA; Janss AJ; Raffel C; Sutton L; Rorke LB; Harper JM; Phillips PC
    Clin Cancer Res; 1997 Mar; 3(3):473-8. PubMed ID: 9815707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.